Published in Diabetes Obes Metab on September 20, 2012
"Turn it off!": diabetes device alarm fatigue considerations for the present and the future. J Diabetes Sci Technol (2013) 1.77
Performance evaluation of three continuous glucose monitoring systems: comparison of six sensors per subject in parallel. J Diabetes Sci Technol (2013) 1.62
Accuracy of two continuous glucose monitoring systems: a head-to-head comparison under clinical research centre and daily life conditions. Diabetes Obes Metab (2014) 1.40
Evaluation of the performance of a novel system for continuous glucose monitoring. J Diabetes Sci Technol (2013) 1.11
Performance evaluation of a continuous glucose monitoring system under conditions similar to daily life. J Diabetes Sci Technol (2013) 1.04
A standard approach to continuous glucose monitor data in pregnancy for the study of fetal growth and infant outcomes. Diabetes Technol Ther (2012) 0.86
Current Trends in Continuous Glucose Monitoring. J Diabetes Sci Technol (2014) 0.86
Professional continuous glucose monitoring in subjects with type 1 diabetes: retrospective hypoglycemia detection. J Diabetes Sci Technol (2013) 0.82
Effect of the approach to insulin therapy on glycaemic fluctuations and autonomic tone in hospitalized patients with diabetes. Diabetes Obes Metab (2013) 0.81
A comparison of continuous intravenous insulin and subcutaneous insulin among patients with type 2 diabetes and congestive heart failure exacerbation. Diabetes Metab Res Rev (2015) 0.79
Accuracy of a Novel Noninvasive Multisensor Technology to Estimate Glucose in Diabetic Subjects During Dynamic Conditions. J Diabetes Sci Technol (2014) 0.78
The role of continuous glucose monitoring in the care of children with type 1 diabetes. Int J Pediatr Endocrinol (2013) 0.78
AP@home: The Artificial Pancreas Is Now at Home. J Diabetes Sci Technol (2016) 0.77
The impact of continuous glucose monitoring on low interstitial glucose values and low blood glucose values assessed by point-of-care blood glucose meters: results of a crossover trial. J Diabetes Sci Technol (2014) 0.77
HypoDE: Research Design and Methods of a Randomized Controlled Study Evaluating the Impact of Real-Time CGM Usage on the Frequency of CGM Glucose Values <55 mg/dl in Patients With Type 1 Diabetes and Problematic Hypoglycemia Treated With Multiple Daily Injections. J Diabetes Sci Technol (2015) 0.76
Glycemic variability during algorithmic titration of insulin among hospitalized patients with type 2 diabetes and heart failure. J Diabetes Complications (2015) 0.75
Continuous Glucose Monitoring: A Perspective on Its Past, Present, and Future Applications for Diabetes Management. Clin Diabetes (2017) 0.75
Effect of Continuous Glucose Monitoring Accuracy on Clinicians' Retrospective Decision Making in Diabetes: A Pilot Study. J Diabetes Sci Technol (2015) 0.75
A toolbox to improve algorithms for insulin-dosing decision support. Appl Clin Inform (2014) 0.75
Sensor-Augmented Insulin Pumps and Hypoglycemia Prevention in Type 1 Diabetes. J Diabetes Sci Technol (2016) 0.75
Continuous Subcutaneous Insulin Infusion in Children: A Pilot Study Validating a Protocol to Avoid Hypoglycemia at Initiation. Front Endocrinol (Lausanne) (2017) 0.75
A Review of the Current Challenges Associated with the Development of an Artificial Pancreas by a Double Subcutaneous Approach. Diabetes Ther (2017) 0.75
Self-monitoring of blood glucose in type 2 diabetes and long-term outcome: an epidemiological cohort study. Diabetologia (2005) 5.47
Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab (2012) 3.68
Hypoglycemic symptoms and frequency of severe hypoglycemia in patients treated with human and animal insulin preparations. Diabetes Care (1991) 3.51
Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab (2012) 3.06
Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care (2000) 2.58
First-time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception (1997) 2.27
Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(*). Diabetes Obes Metab (2011) 2.16
Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab (2007) 2.06
Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial. Gene Ther (2008) 1.88
Subcutaneous continuous glucose monitoring: feasibility of a new microdialysis-based glucose sensor system. Diabetes Care (2001) 1.79
Home Use of an Artificial Beta Cell in Type 1 Diabetes. N Engl J Med (2015) 1.75
Reovirus: viral therapy for cancer 'as nature intended'. Clin Oncol (R Coll Radiol) (2008) 1.74
Insulin glulisine: a faster onset of action compared with insulin lispro. Diabetes Obes Metab (2007) 1.67
A novel insulin formulation with a more rapid onset of action. Diabetologia (2008) 1.57
Oral glucose tolerance test and HbA₁c for diagnosis of diabetes in patients undergoing coronary angiography: [corrected] the Silent Diabetes Study. Diabetologia (2011) 1.55
Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart. Diabetes Care (1998) 1.49
No evidence for accumulation of insulin glargine (LANTUS): a multiple injection study in patients with Type 1 diabetes. Diabet Med (2002) 1.42
Prandial glycaemia after a carbohydrate-rich meal in type I diabetic patients: using the rapid acting insulin analogue [Lys(B28), Pro(B29)] human insulin. Diabet Med (1996) 1.41
Air bubbles in insulin pens. Lancet (1989) 1.39
[Clinical effects and pharmacodynamics of insulin analogs lispro, aspart and glargin]. Dtsch Med Wochenschr (2001) 1.38
Pharmacokinetics and linear exposure of AFRESA compared with the subcutaneous injection of regular human insulin. Diabetes Obes Metab (2009) 1.26
Effect of insulin concentration, subcutaneous fat thickness and skin temperature on subcutaneous insulin absorption in healthy subjects. Diabetologia (1994) 1.25
Sensors for glucose monitoring: technical and clinical aspects. Diabetes Metab Res Rev (2001) 1.24
Prevalence of renal artery stenosis in diabetes mellitus--an autopsy study. J Intern Med (1991) 1.24
Injection-meal interval: recommendations of diabetologists and how patients handle it. Diabetes Res Clin Pract (1999) 1.20
Technosphere/Insulin--proof of concept study with a new insulin formulation for pulmonary delivery. Exp Clin Endocrinol Diabetes (2002) 1.18
Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus. Diabetes Obes Metab (2013) 1.16
First human experiments with a novel non-invasive, non-optical continuous glucose monitoring system. Biosens Bioelectron (2003) 1.15
Smoking is associated with progression of diabetic nephropathy. Diabetes Care (1994) 1.11
Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus. Diabetes Obes Metab (2014) 1.11
Action profile of the rapid acting insulin analogue: human insulin B28Asp. Diabet Med (1993) 1.10
Recurrent use of newer oral contraceptives and the risk of venous thromboembolism. Hum Reprod (2000) 1.06
Comparison of the time-action profiles of U40- and U100-regular human insulin and the rapid-acting insulin analogue B28 Asp. Exp Clin Endocrinol Diabetes (1997) 1.05
Community-based stroke incidence trends from the 1970s through the 1980s in East Germany. Stroke (1995) 1.05
Glucose monitoring by microdialysis: performance in a multicentre study. Diabet Med (2009) 1.04
The RNA-binding protein La contributes to cell proliferation and CCND1 expression. Oncogene (2010) 1.02
The pharmacokinetic and pharmacodynamic properties of different formulations of biphasic insulin aspart: a randomized, glucose clamp, crossover study. Diabetes Technol Ther (2008) 1.01
Insulin aspart in a 30/70 premixed formulation. Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture. Diabetes Care (1997) 1.01
Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin. Diabetes Care (1998) 1.01
How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes. Int J Clin Pract (2010) 1.01
Nutritional behaviour differences in Germany. Rev Environ Health (1996) 0.98
Impact of injection speed and volume on perceived pain during subcutaneous injections into the abdomen and thigh: a single-centre, randomized controlled trial. Diabetes Obes Metab (2014) 0.98
Impact of diabetic nephropathy on pharmacodynamic and Pharmacokinetic properties of insulin in type 1 diabetic patients. Diabetes Care (2001) 0.98
U-100, pH-Neutral formulation of VIAject(®) : faster onset of action than insulin lispro in patients with type 1 diabetes. Diabetes Obes Metab (2011) 0.98
Severe hypoglycemia incidence and predisposing factors in 85 pregnancies of type I diabetic women. Diabetes Care (1992) 0.96
Near-normotension and near-normoglycemia in blind type I diabetic patients with overt diabetic nephropathy. J Diabet Complications (1991) 0.96
Time-action profile of insulin detemir and NPH insulin in patients with type 2 diabetes from different ethnic groups. Diabetes Obes Metab (2006) 0.95
Rapid and long-acting analogues as an approach to improve insulin therapy: an evidence-based medicine assessment. Curr Pharm Des (2001) 0.95
Time-action profile of inhaled insulin. Diabet Med (1997) 0.94
Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes. Diabetes Obes Metab (2014) 0.93
Variability of glucose-lowering effect as a limiting factor in optimizing basal insulin therapy: a review. Diabetes Obes Metab (2013) 0.93
Correlation between blood glucose concentration in diabetics and noninvasively measured tissue optical scattering coefficient. Opt Lett (1997) 0.93
Alternative routes of administration as an approach to improve insulin therapy: update on dermal, oral, nasal and pulmonary insulin delivery. Curr Pharm Des (2001) 0.92
Intra-individual variability of the metabolic effect of inhaled insulin together with an absorption enhancer. Diabetes Care (2000) 0.91
Implications of the traditional and the new ACSM physical activity recommendations on weight reduction in dietary treated obese subjects. Int J Obes Relat Metab Disord (1998) 0.91
Non-invasive glucose monitoring in patients with diabetes: a novel system based on impedance spectroscopy. Biosens Bioelectron (2006) 0.90
Molecular cloning, sequencing and expression of the cDNA of the mitochondrial form of phosphoenolpyruvate carboxykinase from human liver. Biochem J (1996) 0.89
Renal glucose excretion and tubular reabsorption rate related to blood glucose in subjects with type 2 diabetes with a critical reappraisal of the "renal glucose threshold" model. Horm Metab Res (2009) 0.89
Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304. Diabet Med (1999) 0.89
Influence of continuous combined estradiol-norethisterone acetate preparations on insulin sensitivity in postmenopausal nondiabetic women. Menopause (1999) 0.88
Insulin resistance and the effect of insulin on blood pressure in essential hypertension. Hypertension (1998) 0.87
Epidemiology of complications and total treatment costs from diagnosis of Type 2 diabetes in Germany (ROSSO 4). Exp Clin Endocrinol Diabetes (2007) 0.87
Pharmacokinetic and pharmacodynamic properties of taspoglutide, a once-weekly, human GLP-1 analogue, after single-dose administration in patients with Type 2 diabetes. Diabet Med (2009) 0.86
Dynamics of blood electrolytes in repeated hyper- and/or hypoglycaemic events in patients with type 1 diabetes. Diabetologia (2011) 0.86
Time-action profile of the long-acting insulin analogue insulin glargine in comparison to NPH insulin in Japanese volunteers. Diabetes Metab (2003) 0.85
Biosimilar insulins: a European perspective. Diabetes Obes Metab (2014) 0.85
A comparison of insulin detemir and neutral protamine Hagedorn (isophane) insulin in the treatment of diabetes: a systematic review. Diabetes Obes Metab (2013) 0.85
Fluctuation and reproducibility of exposure and effect of insulin glargine in healthy subjects. Diabetes Obes Metab (2008) 0.85
Value of blood pressure self-monitoring as a predictor of progression of diabetic nephropathy. J Hypertens (1999) 0.85
Reduced postprandial glycaemic excursion with biphasic insulin Aspart 30 injected immediately before a meal. Diabet Med (2004) 0.84
Premixed formulations of insulin lispro. Activity profiles in type 1 diabetic patients. Diabetes Care (1999) 0.84
Electrocardiographic changes during insulin-induced hypoglycemia in healthy subjects. Horm Metab Res (1998) 0.84
Hyperinsulinaemia is not linked with blood pressure elevation in patients with insulinoma. Diabetologia (1992) 0.83
Noninvasive glucose measurement by monitoring of scattering coefficient during oral glucose tolerance tests. Non-Invasive Task Force. Diabetes Technol Ther (2000) 0.83
Do insulin-treated diabetic patients use an injection-meal-interval in daily life? Diabet Med (1995) 0.83
[Incidence and prognosis of stroke episodes in the East German population. Results from a stroke register 1985-1988]. Nervenarzt (1994) 0.83
How do patients' preferences compare to the present spectrum of diabetes research? Exp Clin Endocrinol Diabetes (2012) 0.83
Insulin detemir under steady-state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with Type 1 diabetes. Diabet Med (2006) 0.82
The pharmacokinetic and pharmacodynamic properties of biphasic insulin Aspart 70 (BIAsp 70) are significantly different from those of biphasic insulin Aspart 30 (BIAsp 30). Exp Clin Endocrinol Diabetes (2005) 0.82
The action profiles of human NPH insulin preparations. Diabet Med (1989) 0.82
The blood glucose lowering effects of exercise and glibenclamide in patients with type 2 diabetes mellitus. Diabet Med (1998) 0.82
Insulin aspart has a shorter duration of action than human insulin over a wide dose-range. Diabetes Obes Metab (2012) 0.81
Primary rat hepatocytes as in vitro system for gene expression studies: comparison of sandwich, Matrigel and 2D cultures. Arch Toxicol (2008) 0.81
Lack of a role of the interferon-stimulated response element-like region in interferon alpha -induced suppression of Hepatitis B virus in vitro. J Biol Chem (2000) 0.81
The rapid-acting properties of insulin aspart are preserved in elderly people with type 2 diabetes. Diabetes Obes Metab (2009) 0.81